Terms: = Breast cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
85 results:
1. Discovery of ganoderic acid A (GAA) PROTACs as mdm2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
2. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract] [Full Text] [Related]
3. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract] [Full Text] [Related]
4. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
5. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
6. ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with mdm2.
Ma X; Fan M; Yang K; Wang Y; Hu R; Guan M; Hou Y; Ying J; Deng N; Li Q; Jiang G; Zhang Y; Zhang X
Cancer Sci; 2023 Nov; 114(11):4237-4251. PubMed ID: 37700392
[TBL] [Abstract] [Full Text] [Related]
7. GSG2 facilitates the progression of human breast cancer through mdm2-mediated ubiquitination of E2F1.
Tang Y; Dai G; Yang Y; Liu H
J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
[TBL] [Abstract] [Full Text] [Related]
8. Identification of mdm2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Zheng J; Miao F; Wang Z; Ma Y; Lin Z; Chen Y; Kong X; Wang Y; Zhuang A; Wu T; Li W
Life Sci; 2023 Aug; 327():121832. PubMed ID: 37276911
[TBL] [Abstract] [Full Text] [Related]
9. Role of p53 in breast cancer progression: An insight into p53 targeted therapy.
Marvalim C; Datta A; Lee SC
Theranostics; 2023; 13(4):1421-1442. PubMed ID: 36923534
[TBL] [Abstract] [Full Text] [Related]
10. GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to paclitaxel by forming a vicious cycle with IGF1/IGF1R signaling pathway.
Liu Z; Meng D; Wang J; Cao H; Feng P; Wu S; Wang N; Dang C; Hou P; Xia P
Cell Death Dis; 2022 Aug; 13(8):751. PubMed ID: 36042202
[TBL] [Abstract] [Full Text] [Related]
11. MIR4435-2HG Is a Potential Pan-cancer Biomarker for Diagnosis and prognosis.
Zhong C; Xie Z; Zeng LH; Yuan C; Duan S
Front Immunol; 2022; 13():855078. PubMed ID: 35784328
[TBL] [Abstract] [Full Text] [Related]
12. The
Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
[TBL] [Abstract] [Full Text] [Related]
13. GATA3 and mdm2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G; Coto-Llerena M; Gallon J; Kancherla V; Taha-Mehlitz S; Marinucci M; Konantz M; Srivatsa S; Montazeri H; Panebianco F; Tirunagaru VG; De Menna M; Paradiso V; Ercan C; Dahmani A; Montaudon E; Beerenwinkel N; Kruithof-de Julio M; Terracciano LM; Lengerke C; Jeselsohn RM; Doebele RC; Bidard FC; Marangoni E; Ng CKY; Piscuoglio S
Commun Biol; 2022 Apr; 5(1):373. PubMed ID: 35440675
[TBL] [Abstract] [Full Text] [Related]
14. Expression profile of tumour suppressor protein p53 and its regulator mdm2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana.
Opoku F; Bedu-Addo K; Titiloye NA; Atta Manu E; Ameh-Mensah C; Duduyemi BM
PLoS One; 2021; 16(10):e0258543. PubMed ID: 34695137
[TBL] [Abstract] [Full Text] [Related]
15. Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP.
Chen Y; Hao Q; Wang S; Cao M; Huang Y; Weng X; Wang J; Zhang Z; He X; Lu H; Zhou X
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266953
[TBL] [Abstract] [Full Text] [Related]
16. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract] [Full Text] [Related]
17. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive breast cancer.
Yang X; Wu D; Yuan S
Technol Cancer Res Treat; 2020; 19():1533033820962140. PubMed ID: 33034269
[TBL] [Abstract] [Full Text] [Related]
18. E2F1-activated SPIN1 promotes tumor growth via a mdm2-p21-E2F1 feedback loop in gastric cancer.
Lv BB; Ma RR; Chen X; Zhang GH; Song L; Wang SX; Wang YW; Liu HT; Gao P
Mol Oncol; 2020 Oct; 14(10):2629-2645. PubMed ID: 32767629
[TBL] [Abstract] [Full Text] [Related]
19. Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
Ruhnau J; Parczyk J; Danker K; Eickholt B; Klein A
BMC Cancer; 2020 Jul; 20(1):617. PubMed ID: 32615946
[TBL] [Abstract] [Full Text] [Related]
20. Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
Pu Q; Lv YR; Dong K; Geng WW; Gao HD
BMC Cancer; 2020 Jun; 20(1):583. PubMed ID: 32571254
[TBL] [Abstract] [Full Text] [Related]
[Next]
